ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award
ADC Therapeutics (ADCT) has granted its CFO, Jose Carmona, 203,700 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs will vest on June 30, 2027, or earlier under specific termination events, provided continued employment. This award increases his direct holdings to 938,076 common shares and is considered an equity award rather than a market transaction.
ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares
ADC Therapeutics' Chief Medical Officer, Zaki Mohamed, was granted 213,900 Restricted Stock Units (RSUs) on June 30, 2026, as an equity award. This compensation-related grant increases his direct holdings to 896,317 common shares. The RSUs will vest on the earlier of June 30, 2027, or a qualifying termination, contingent on his continued employment.
ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer
ADC Therapeutics (ADCT) announced that its Chief Legal Officer, Peter J. Graham, was granted 221,100 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs, which represent common shares, will vest on the earlier of June 30, 2027, or specific termination events, provided he remains employed. Following this grant, Graham's direct holdings in the company now total 841,640 common shares.
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics SA (NYSE: ADCT) has announced an inducement grant of options to purchase 17,000 common shares for a new employee. This grant, approved by the Compensation Committee, aims to retain top talent and relies on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The options will vest over four years, subject to continued employment, demonstrating the company's commitment to strategic talent acquisition.
ADC Therapeutics Completes Enrollment in LOTIS-7, Advancing ZYNLONTA-Glofitamab Combination in DLBCL
ADC Therapeutics has completed enrollment of 100 patients in its Phase 1b LOTIS-7 trial, evaluating a combination of ZYNLONTA and glofitamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial has shown an 89.8% overall response rate and a 77.6% complete response rate in interim data. Full data from the study is expected in Q4 2026, and the company plans to explore regulatory pathways for the combination.
ADC Therapeutics completes LOTIS-7 trial enrollment
ADC Therapeutics has completed enrollment for its Phase 1b LOTIS-7 clinical trial, which investigates ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 100 patients and aims to assess the safety and early efficacy of the combination therapy. Full clinical data from the trial are anticipated in the fourth quarter of 2026.
ADC Therapeutics completes enrollment in LOTIS-7 trial
ADC Therapeutics has completed enrollment in its LOTIS-7 Phase 1b clinical trial, evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma. The company reported promising initial response rates from earlier data and anticipates sustained profitability by fiscal year 2026. Despite a recent stock decline, analysis suggests the company is undervalued, with full trial data expected by the end of 2026.
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study enrolled 100 patients at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab, with full data expected in the fourth quarter of 2026. Prior data showed promising results with an 89.8% overall response rate and 77.6% complete response.
ETFs Investing in ADC Therapeutics Ltd Stocks
This article lists several ETFs that hold ADC Therapeutics Ltd (ADCT) stocks, providing financial details for each fund. The ETFs include those focused on small-cap growth, biotechnology, micro-cap companies, and healthcare innovation, with varying management styles and expense ratios. Investors can use this information to identify funds with exposure to ADCT and assess their performance metrics.
ADC Therapeutics SA(NYSE: ADCT) added to Russell Microcap Value Benchmark Index
ADC Therapeutics SA (ADCT) has been added to the Russell Microcap Value Benchmark Index. This news follows a previous announcement on the same day that the company was added to the Russell 2000 Value Benchmark. The company, a clinical-stage oncology drug developer, recently reported its Q1 2026 earnings and is undergoing a workforce reduction.
Enterprise value to revenue forward of ADC Therapeutics SA – NYSE:ADCT
This article provides financial information for ADC Therapeutics SA (NYSE: ADCT), specifically focusing on its enterprise value to revenue forward metric. The data is presented within the context of TradingView's platform, indicating that the metrics are available for investor analysis. The content is primarily a data placeholder within a financial information service.
Price to earnings forward of ADC Therapeutics SA – NYSE:ADCT
This article provides a brief financial data point for ADC Therapeutics SA (NYSE:ADCT), specifically regarding its price-to-earnings forward ratio. The content is sparse, indicating "Period Value Change Change %" but without specific numerical data. It appears to be a stub or a section focused on displaying this particular financial metric for the company.
ADC Therapeutics Ltd Actuals & Estimates (NYSE:ADCT)
This article provides an overview of ADC Therapeutics SA (NYSE:ADCT) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price targets, upcoming earnings dates, and past financial results like revenue and net income. The article also touches on company specifics such as employee count, EBITDA, and technical analysis recommendations.
ADC Therapeutics launches restructuring around ZYNLONTA
ADC Therapeutics (NYSE:ADCT) is undergoing a strategic reorganization focusing on its ZYNLONTA franchise and related clinical trials. The restructuring involves an estimated 17% workforce reduction, expected to save $10 million annually, and aims to extend the company's cash runway into 2028. This move highlights the company's efforts to prioritize its late-stage oncology pipeline and control costs.
ADC Therapeutics (NYSE: ADCT) trims workforce 17% to back ZYNLONTA trials and extend cash runway
ADC Therapeutics announced a strategic reorganization involving a 17% global workforce reduction to focus on its ZYNLONTA franchise. This move is expected to generate $10 million in annualized cost savings against $3 million in one-time charges, extending the company’s cash runway into at least 2028. The reorganization supports key regulatory milestones, including an upcoming FDA meeting for LOTIS-5 in August 2026 and an sBLA submission in Q4 2026.
ADC Therapeutics plans 17% workforce cut to save ~$10M annually, $3M one-time charges
ADC Therapeutics announced a global workforce reduction of approximately 17% to achieve about $10 million in annualized cost savings. This reduction is primarily due to the completion of the LOTIS-5 and LOTIS-7 programs and aims to enhance financial flexibility. The company expects one-time pre-tax charges of approximately $3 million, mostly in Q2 2026, and is preparing for a pre-sBLA meeting with the FDA in August 2026 for LOTIS-5.
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
ADC Therapeutics (NYSE: ADCT) has announced a strategic reorganization, including a 17% global workforce reduction, to enhance financial flexibility and focus on ZYNLONTA® growth. The company expects to save approximately $10 million annually, driven by the anticipated completion of LOTIS-5 and LOTIS-7 trials in 2026. Key upcoming milestones include a pre-sBLA meeting with the FDA in August 2026 for ZYNLONTA in r/r DLBCL, with an sBLA submission expected in Q4 2026, and full data from the LOTIS-7 trial by year-end.
ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details
ADC Therapeutics (ADCT) announced a 17% workforce reduction to focus on its ZYNLONTA franchise and upcoming regulatory milestones, including a pre-supplemental Biologics License Application with the FDA in August 2026. This move is expected to generate $10 million in annualized cost savings and extend the company's cash runway through at least 2028. The company aims to increase financial flexibility and continue developing ZYNLONTA for various blood cancers.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) following a significant drop in stock price. This investigation comes after ADC announced topline data from its Phase 3 LOTIS-5 trial, where their treatment, ZYNLONTA, showed extended progression-free survival but also a higher number of deaths compared to the control group. Shareholders are encouraged to contact the firm to assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) securities. This investigation follows a significant drop in ADC's stock price after the announcement of topline data from its Phase 3 LOTIS-5 trial, which showed an extension in progression-free survival but also a higher number of deaths in the Zynlonta treatment arm compared to the immunotherapy arm. Shareholders are encouraged to contact the firm to assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADC Therapeutics SA (ADCT) following a significant drop in its stock price. This investigation comes after the announcement of top-line data from ADC's Phase 3 LOTIS-5 trial, which, despite extending progression-free survival, reported a higher number of deaths for patients treated with ZYNLONTA® compared to the immunotherapy arm. Shareholders are encouraged to learn more about the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (ADCT) on behalf of investors. This investigation follows a significant drop in ADC's stock price after the company released topline data from its Phase 3 LOTIS-5 trial for ZYNLONTA®, which, despite extending progression-free survival, reported a higher number of deaths in the Zynlonta arm compared to the immunotherapy arm. Investors are advised to contact the firm for more information regarding potential class action involvement.
ADC Therapeutics SA (ADCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for ADC Therapeutics SA (ADCT), detailing its business segments. It shows that Product sales account for 90.41% of revenue, followed by License revenue at 6.15%, and Royalties at 3.45%. The article also notes that relevant regional data for FY2025 has not yet been disclosed by the company.
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADC Therapeutics SA (NYSE:ADCT) following a significant stock price drop. This drop occurred after the company announced Phase 3 trial data for ZYNLONTA®, which, despite extending progression-free survival, reported a higher number of deaths in the Zynlonta arm compared to the immunotherapy arm. Shareholders who purchased ADC securities are encouraged to contact the firm to learn more and potentially assist in the investigation.
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) securities. This investigation follows the announcement of topline data from ADC's Phase 3 LOTIS-5 trial, where ZYNLONTA® extended progression-free survival but showed significantly higher deaths compared to the immunotherapy arm. Following this news, ADC's stock price dropped by 66.56%, prompting the firm to encourage affected investors to inquire about the securities investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential claims against ADC Therapeutics SA (NYSE: ADCT) on behalf of investors. This investigation follows a significant drop in ADC's stock price after the company announced topline data from its Phase 3 LOTIS-5 trial, revealing a higher number of deaths in the ZYNLONTA® treatment arm compared to the immunotherapy arm. The law firm is seeking to determine if ADC and its officers engaged in securities fraud or other unlawful business practices.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADC Therapeutics SA (ADCT) following a significant drop in its stock price. This drop occurred after the company released topline data from its Phase 3 LOTIS-5 trial, which, despite extending progression-free survival, reported a higher number of deaths in the ZYNLONTA® treatment arm compared to the control group. The law firm is encouraging investors who purchased ADC securities to connect and assist with the investigation.
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) securities. This investigation follows a significant drop in ADC's stock price after the announcement of topline data from its Phase 3 LOTIS-5 trial, which showed an extended progression-free survival but also a higher number of deaths for patients treated with ZYNLONTA®. Investors are encouraged to contact the firm to learn more and assist the investigation.
ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA Data - Has The Bull Case Changed?
ADC Therapeutics (ADCT) recently reported mixed Phase 3 LOTIS-5 data for ZYNLONTA, showing improved progression-free survival in lymphoma but also higher rates of serious adverse events, particularly in older patients. This mixed profile is now central to discussions with regulators and could impact ZYNLONTA's label and the company's future growth. The article explores how this data might affect ADC Therapeutics' investment narrative, emphasizing dilution risk due to ongoing losses and regulatory uncertainty, while also noting that analysts projected significant revenue and earnings growth by 2028 based on a $7.50 fair value.
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL - Slideshow
ADC Therapeutics SA (ADCT) has published a slide deck discussing the results of its Phase III LOTIS-5 trial and outlining the next steps for its treatment of Diffuse Large B-cell Lymphoma (DLBCL). The article highlights the company's detailed presentation on the trial's findings.
ADC Therapeutics (ADCT) director RSU grant and 12,600-share tax withholding
ADC Therapeutics (ADCT) director Jean-Pierre Bizzari received an annual grant of 45,000 restricted stock units (RSUs) for his board service. To cover tax obligations on previously vested RSUs, 12,600 common shares were withheld by the company at $3.08 per share. Following these transactions, Bizzari directly holds 139,302 common shares in ADC Therapeutics.
Why Is ADC Therapeutics Stock Falling Thursday?
ADC Therapeutics (ADCT) stock is falling after the company announced that its Phase 3 LOTIS-5 trial for ZYNLONTA showed elevated serious and Grade 5 adverse events, despite meeting its primary endpoint of progression-free survival in patients with relapsed or refractory diffuse large B-cell lymphoma. The company plans to discuss the benefit-risk profile with the FDA and prepare for an sBLA submission in Q4 2026. This news led to a significant drop in ADCT shares during premarket trading.
ADC Therapeutics’ Zynlonta Clears Phase III PFS Bar But Safety Concerns Cloud FDA Path
ADC Therapeutics' drug Zynlonta has met its primary endpoint for progression-free survival in a Phase III trial for diffuse large B-cell lymphoma (DLBCL). Despite this positive efficacy result, ongoing safety concerns, particularly regarding respiratory issues and patient deaths, are expected to complicate its path to FDA approval for broader indications. The company has previously halted studies due to these safety issues.
ADC Therapeutics’ Zynlonta Clears Phase III PFS Bar But Safety Concerns Cloud FDA Path
ADC Therapeutics' drug Zynlonta successfully met its primary endpoint of progression-free survival in a Phase III trial for diffuse large B-cell lymphoma (DLBCL). However, the drug's path to FDA approval is complicated by safety concerns, including previous study halts due to patient deaths and respiratory issues. This development comes as DLBCL remains the most common non-Hodgkin lymphoma.
ADC Therapeutics falls on confirmatory trial data for lymphoma therapy
ADC Therapeutics (ADCT) shares fell following the announcement of confirmatory Phase 3 trial data for their lymphoma therapy, ZYNLONTA, at the ASCO annual meeting. While the data reinforced the drug's activity in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the market reaction indicates some disappointment despite the positive affirmation.
ADC Therapeutics (ADCT) director receives RSU award and shares withheld for taxes
ADC Therapeutics (ADCT) director Ron Squarer received an annual grant of 45,000 Restricted Stock Units (RSUs) for board service on June 1, 2026. Two days later, 15,196 common shares were withheld by the company to cover tax obligations related to previously vested RSUs, at a reference price of $3.08 per share. Following these transactions, Mr. Squarer directly holds 123,431 common shares.
ADCT stock plunges on safety concerns despite positive lymphoma data
The article discusses the significant drop in ADC Therapeutics' stock (ADCT) despite reporting positive data for its lymphoma drug Zynlonta. The decline is attributed to safety concerns raised during the presentation. Investors are seemingly prioritizing potential side effects over the drug's efficacy in the current market.
Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise
ADC Therapeutics' ZYNLONTA, in combination with rituximab (Lonca-R), successfully met its primary endpoint in the Phase 3 LOTIS-5 trial for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), showing statistically significant improvement in progression-free survival. Despite positive efficacy, the trial highlighted increased serious adverse events and treatment-related deaths in the Lonca-R arm, especially in older patients, raising concerns about its benefit-risk profile. The company plans a supplemental Biologics License Application (sBLA) submission in Q4 2026, aiming for full FDA approval and label expansion into earlier lines of treatment, while also exploring further combinations and indications.
Zynlonta Lotis position in DLBCL strains ADC shares
ADC Therapeutics SA attributed the death imbalance in its phase III Lotis-5 confirmatory trial for Zynlonta to the advanced age of patients. The trial is testing Zynlonta in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma. Wall Street reacted negatively to the news, causing ADC Therapeutics' shares (NYSE:ADCT) to drop significantly by 57%.
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADC Therapeutics (ADCT) shares plummeted over 53% despite positive efficacy results from a phase III study of its drug Zynlonta combined with Rituxan for lymphoma. Investors were primarily concerned by the safety findings, which revealed higher rates of serious adverse events, treatment discontinuations, and fatal adverse events in the Zynlonta treatment arm compared to the control group. The company plans to engage with the FDA and prepare for a regulatory filing in Q4 2026, while also exploring cost-reduction measures.
ADC Therapeutics Posts Downbeat Q1 Earnings, Joins Julong Holding And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
ADC Therapeutics SA (NYSE: ADCT) saw its shares plummet in pre-market trading after concerns surrounding trial safety for its lymphoma therapy, Zynlonta, despite the drug meeting its primary endpoint. This significant dip of over 50% contributed to a broader downward trend in Thursday's pre-market session, with other companies like Julong Holding, Apartment Investment and Management Company, PVH Corp, and Netskope Inc also experiencing substantial declines due to various negative corporate news, public offerings, or analyst downgrades.
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics shares dropped significantly after a late-stage trial for its blood cancer drug, Zynlonta, showed a higher death rate among treated patients, despite meeting its primary goal of improving progression-free survival. The study, testing Zynlonta with Roche's Rituxan, reported 27 deaths in the treatment arm compared to 9 in the control arm, with most deaths in the treatment arm occurring in older patients. The company plans to discuss these results with the U.S. FDA in August, aiming for a supplemental application later this year for full approval.
ADC Thera falls on trial data for lymphoma drug (ADCT:NYSE)
ADC Therapeutics (ADCT) stock hit a new 52-week low after RBC Capital Markets downgraded it due to topline data from a Phase 3 trial for a combination regimen with its lymphoma therapy Zynlonta. The trial showed modest progression-free survival benefit, no clear overall survival improvement, and a higher rate of serious adverse events and patient deaths in the treatment arm. RBC's downgrade cited limited efficacy gains and a significant death risk imbalance in the data.
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics announced positive topline data from its Phase 3 LOTIS-5 trial, showing ZYNLONTA in combination with rituximab met its primary endpoint of progression-free survival in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The combination demonstrated statistical significance with improved complete response rates, and no detrimental effect on overall survival compared to standard immunochemotherapy. The company plans to discuss these results with the U.S. FDA for a supplemental Biologics License Application filing in Q4 2026.
ADC Therapeutics stock plunges on trial safety concerns
ADC Therapeutics SA (NYSE:ADCT) shares plummeted 45.9% after-hours following topline results from its Phase 3 LOTIS-5 trial. While the trial met its primary endpoint for treating relapsed or refractory diffuse large B-cell lymphoma, significant safety concerns, including higher rates of serious adverse events and treatment discontinuations, overshadowed the efficacy. The company plans to discuss the benefit-risk profile with the FDA for a supplemental Biologics License Application.
Zynlonta combo slows lymphoma progression to 6.1 months vs 4.7 in Phase 3 LOTIS-5
ADC Therapeutics announced positive topline results from its Phase 3 LOTIS-5 trial for ZYNLONTA plus rituximab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The combination met its primary endpoint, significantly improving progression-free survival to 6.1 months compared to 4.7 months for the control arm, and showed higher response rates. While overall survival was not detrimentally affected, there were increased rates of serious adverse events and treatment withdrawals, particularly in older patients, which the company plans to discuss with the FDA ahead of a planned sBLA submission in Q4 2026.
ADC Therapeutics' Drug Regimen to Treat B-Cell Lymphoma Meets Primary Endpoint of Progression-Free Survival in Phase 3 Trial
ADC Therapeutics announced that its drug regimen for B-Cell Lymphoma successfully met the primary endpoint of progression-free survival in a Phase 3 trial. The news was published on June 3, 2026, at 5:13 pm EDT. Further details about the LOTIS-5 study and its topline results for ZYNLONTA in combination with Rituximab for relapsed or refractory diffuse large B-cell lymphoma were also recently released by the company.
LOTIS-5 trial: ADC Therapeutics (NYSE: ADCT) shows PFS gain but higher toxicity
ADC Therapeutics (NYSE: ADCT) announced positive topline Phase 3 LOTIS-5 results for ZYNLONTA plus rituximab in relapsed or refractory diffuse large B-cell lymphoma, meeting its primary endpoint with improved progression-free survival (6.1 versus 4.7 months) and higher response rates. However, the treatment also showed higher serious adverse events, withdrawals, and Grade 5 events, particularly in older patients. The company plans a pre-sBLA FDA meeting in August and a supplemental BLA submission in Q4 2026.
ADC Therapeutics reports positive LOTIS-5 PFS results; plans pre-sBLA meeting and Q4 2026 sBLA
ADC Therapeutics announced positive topline data from its Phase 3 LOTIS-5 trial, showing a statistically significant improvement in progression-free survival (PFS) for ZYNLONTA plus rituximab compared to R-GemOx. The company plans a pre-sBLA meeting with the FDA in August and aims for an sBLA submission in Q4 2026, while also exploring options for value maximization and cost reduction.
ADC Therapeutics Announces Topline Results From LOTIS-5 Phase 3 Confirmatory Trial Of ZYNLONTA In Combination with Rituximab In Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics announced topline results from its Phase 3 LOTIS-5 trial, showing that ZYNLONTA combined with rituximab met the primary endpoint of progression-free survival in patients with relapsed or refractory diffuse large B-cell lymphoma. The combination also showed no detrimental effect on overall survival and achieved higher complete response rates, despite higher rates of serious adverse events and Grade 5 TEAEs in the test arm, particularly in older patients. The drug is already approved by the FDA and EMA for similar conditions, and this confirmatory trial supports its clinical benefit.
